From: Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study
Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
---|---|---|---|---|---|---|---|---|
Drug regimen | ETB | ETB | ETB | ETB | ||||
RIF | RIF | RIF | RIF | |||||
ETN | ETN | ETN | ETN | |||||
ETB | ETB | ETB | ETB | |||||
PRZ | PRZ | PRZ | PRZ | |||||
PRZ | PRZ | PRZ | PRZ | |||||
CPF | CPF | CPF | CPF | |||||
KAN | KAN | KAN | KAN | |||||
KAN | KAN | AMK | KAN | |||||
Gain BMI (Kg/m 2 ) | 1.8 | 0.4 | 0.4 | 0.4 | 0.3 | 2.2 | 1.8 | - 2.1! |
Sputum smear status | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
Sputum culture status | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
Conversion time | 2 mo. | 3 mo. | 3 mo. | 1 mo. | 3 mo. | 2 mo. | 2 mo. | 3 mo. |
Thorax X-ray | Residual fibrosis | Reabsorption and residual fibrosis | Residual bilateral fibrosis. | Lesions resolution | Residual fibrosis | Lesions size reduction | Residual fibrosis | Lesions size reduction |
GSR (mm/h) | 5 | 48 | 26 | 40 | 42 | 20 | 23 | 77 |